IOVA - ライオン・バイオテクノロジ―ズ （Iovance Biotherapeutics Inc.） ライオン・バイオテクノロジ―ズIOVAのチャート
IOVAの企業情報
| symbol | IOVA |
|---|---|
| 会社名 | Iovance Biotherapeutics Inc （ライオン・バイオテクノロジ―ズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Biotechnology: Biological Products (No Diagnostic Substances) |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 アイオワンス･バイオセラピューティクス(Iovance Biotherapeutics Inc.)(旧名：Lion Biotechnologies Inc)は臨床段階バイオ医薬品会社である。同社は患者自身の免疫システムによって癌細胞を根絶する癌免疫療法製品の開発･商業化に従事する。同社ののリードプログラムは転移性メラノーマの治療のために患者の腫瘍に由来するT細胞である腫瘍浸潤リンパ球を利用する養子細胞療法である。同社は子宮頸癌および頭頸部癌を治療するためにLN-145を開発中である。同社は眼科用メラノーマ、膀胱癌、乳癌、肺癌などの他の固形腫瘍適応症における非改変TILを評価するために国立癌研究所と共同研究を行う。同社はチェックポイントインヒビターKeytrudaと組み合わせてTILを評価するためにNCIと協力する。 ライオン・バイオテクノロジ―ズは米国のバイオ医薬品会社。転移性黒色腫、およびその他固形腫瘍に焦点を充てた新薬の開発に注力する。転移性黒色腫、およびその他固形腫瘍治療向けに、自家腫瘍浸潤リンパ球を使用した養子免疫療法の開発と商品化を手掛ける。本社はカリフォルニア州。 Iovance Biotherapeutics aims to improve patient care by making T cell-based immunotherapies broadly accessible for the treatment of patients with solid tumors and blood cancers. Tumor infiltrating lymphocyte (TIL) therapy uses a patient's own immune cells to attack cancer. TIL cells are extracted from a patient's own tumor tissue, expanded through a proprietary process, and infused back into the patient. Upon infusion, TIL reach tumor tissue, where they attack cancer cells. The company has completed dosing in pivotal programs in patients with metastatic melanoma and cervical cancer. In addition, the company's TIL therapy is being investigated in a registration-supporting study for the treatment of patients with locally advanced, recurrent or metastatic non-small cell lung cancer. Clinical studies are also underway to evaluate TIL in earlier stage cancers in combination with currently approved treatments, and to investigate Iovance peripheral blood lymphocyte (PBL) T cell therapy for blood cancers. |
| 本社所在地 | 999 Skyway Road Suite 150 San Carlos CA 94070 USA |
| 代表者氏名 | Iain D. Dukes イアン・D・デュークス |
| 代表者役職名 | Chairman of the Board 取締役会会長 |
| 電話番号 | +1 650-260-7120 |
| 設立年月日 | 39326 |
| 市場名 | NASDAQ National Market System |
| ipoyear | ―年 |
| 従業員数 | 63人 |
| url | www.lionbio.com |
| nasdaq_url | https://www.nasdaq.com/symbol/iova |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -105.72800 |
| 終値（lastsale） | 10.92 |
| 時価総額（marketcap） | 1043866485.48 |
| 時価総額 | 時価総額（百万ドル） 1134.795 |
| 売上高 | 売上高（百万ドル） 0.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 858.70200 |
| 当期純利益 | 当期純利益（百万ドル） -105.17800 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Iovance Biotherapeutics Inc revenues was not reported. Net loss increased 30% to $57.2M. Higher net loss reflects Research and development - Balancing val increase of 21% to $40.1M (expense) General_Administrative - Balancing val increase of 81% to $8.8M (expense) Stock-based Compensation in SGA increase of 50% to $4.9M (expense). |
IOVAのテクニカル分析
IOVAのニュース
US Stocks Start Week On Lower Note; Dow Tumbles 250 Points 2022/12/05 15:05:21 Benzinga
U.S. stocks traded lower this morning, with the Dow Jones falling around 250 points on Monday. Following the market opening Monday, the Dow traded down 0.74% to 34,173.39 while the NASDAQ fell 0.48% to 11,406.06. The S&P 500 also fell, dropping, 0.71% to 4,042.60. Also check this: Bitcoin Surpasses This Key Level; Axie Infinity Emerges As Top Gainer Leading and Lagging Sectors Energy shares rose by 0.1% on Monday. Leading the sector was strength from PHX Minerals Inc. (NYSE: PHX ) and OPAL Fuels Inc. (NASDAQ: OPAL ). In trading on Monday, consumer discretionary shares fell by 1.6%. Top Headline The ISM services index climbed to 56.5 in November from previous reading of 54.4. Equities Trading UP Digital Brands Group, Inc. (NASDAQ: DBGI ) shares shot up 22% to $4.57. Digital Brands Group, last week, announced a $10 million public offering. Shares of EHang Holdings Limited (NASDAQ: EH ) got a boost, shooting 19% to $6.78. EHang Holdings appointed Mr. Nick Ning Yang as a new director to the Company’s Board of Directors.
After Sinking 3.05% During Past Week, Is Iovance Biotherapeutics Inc. (NASDAQ: IOVA) Still A Buy? 2022/12/02 12:00:00 Marketing Sentinel
Iovance Biotherapeutics Inc. (NASDAQ:IOVA)’s traded shares stood at 5.97 million during the last session, with the company’s beta value hitting 0.42. At the close of trading, the stock’s price was $6.41, to imply an increase of 0.16% or $0.01 in intraday trading. The IOVA share’s 52-week high remains $20.60, putting it -221.37% down since that … After Sinking 3.05% During Past Week, Is Iovance Biotherapeutics Inc. (NASDAQ: IOVA) Still A Buy? Read More »
63K Reasons To Be Bullish On Iovance Biotherapeutics Stock 2022/12/01 15:02:58 Benzinga
Merrill A McPeak , Director at Iovance Biotherapeutics (NASDAQ: IOVA ), reported a large insider buy on November 30, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Wednesday showed that McPeak purchased 10,000 shares of Iovance Biotherapeutics. The total transaction amounted to $63,099. Iovance Biotherapeutics shares are trading up 3.75% at $6.64 at the time of this writing on Thursday morning. Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm. The Importance of Insider Transactions Insider transactions shouldn''t be used primarily to … Full story available on Benzinga.com
What will the future hold for Iovance Biotherapeutics Inc. (NASDAQ:IOVA) stock? 2022/11/29 17:40:00 US Post News
In the current trading session, Iovance Biotherapeutics Inc.’s (IOVA) stock is trading at the price of $6.14, a gain of 3.28% over last night’s close. So, the stock is trading at a price that is -70.17% less than its 52-week high of $20.60 and 13.38% better than its 52-week low of $5.42. Based on the […]
Iovance Stock: Rolling BLA Development Signals More Upside (NASDAQ:IOVA) 2022/11/29 16:44:36 Seeking Alpha
In the latest filing, Iovance stated that they received guidance from the FDA for lifileucel''s rolling BLA. See why we recommend a buy on IOVA stock.
What will the future hold for Iovance Biotherapeutics Inc. (NASDAQ:IOVA) stock? 2022/11/29 17:40:00 US Post News
In the current trading session, Iovance Biotherapeutics Inc.’s (IOVA) stock is trading at the price of $6.14, a gain of 3.28% over last night’s close. So, the stock is trading at a price that is -70.17% less than its 52-week high of $20.60 and 13.38% better than its 52-week low of $5.42. Based on the […]
Iovance Stock: Rolling BLA Development Signals More Upside (NASDAQ:IOVA) 2022/11/29 16:44:36 Seeking Alpha
In the latest filing, Iovance stated that they received guidance from the FDA for lifileucel''s rolling BLA. See why we recommend a buy on IOVA stock.
Iovance Biotherapeutics Inc. (NASDAQ:IOVA) Shares Dropped -14.68% In A Week. Can It Continue Rising? 2022/11/25 14:00:00 Marketing Sentinel
In last trading session, Iovance Biotherapeutics Inc. (NASDAQ:IOVA) saw 3.37 million shares changing hands with its beta currently measuring 0.46. Company’s recent per share price level of $6.22 trading at -$0.06 or -0.96% at ring of the bell on the day assigns it a market valuation of $1.05B. That closing price of IOVA’s stock is … Iovance Biotherapeutics Inc. (NASDAQ:IOVA) Shares Dropped -14.68% In A Week. Can It Continue Rising? Read More »
Why Iovance Biotherapeutics Is Crashing Today 2022/11/18 18:06:41 The Motley Fool
The FDA is asking the drug development outfit for more information regarding its tumor-infiltrating lymphocyte therapy.
Iovance Biotherapeutics Pushes FDA Rolling Submission Deadline Into Next Year For Its Lead Skin Cancer Candidate 2022/11/18 17:09:54 Benzinga
Iovance Biotherapeutics Inc (NASDAQ: IOVA ) announced that its ongoing rolling Biologics License Application (BLA) submission to the FDA for lifileucel is expected to be completed in the first quarter of 2023 as against Q4 FY22 expected earlier . As part of an amendment to the ongoing investigational new drug application submitted during Q3, Iovance received recent FDA feedback … Full story available on Benzinga.com
Iovance Biotherapeutics to Host First Quarter Financial Results Conference Call and Webcast on Thursday, May 5, 2022 2022/04/26 11:30:00 GlobeNewswire
SAN CARLOS, Calif., April 26, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report its first quarter financial results on Thursday, May 5, 2022. Management will host a conference call and live audio webcast to discuss these results and provide a corporate update at 4:30 p.m. ET.
Iovance price target raised at Baird citing FDA feedback on melanoma candidate 2022/04/07 18:07:34 Kwhen Finance
The Daily Biotech Pulse: BioXcel''s Igalmi Gets FDA Nod, Citius Spikes On Positive Phase 3 Data, Iovance Receives Positive Regulatory Feedback For Skin Cancer Therapy 2022/04/06 12:02:14 Benzinga
Here''s a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Iovance Plans to File For Melanoma Therapy Approval In August Following Positive FDA Feedback Iovance Biotherapeutics, Inc. (NASDAQ: IOVA ) said the U.S. Food and Drug Administration on Friday provided a positive feedback regarding its proposed matrix of potency assays for its upcoming biologics license application for lifileucel in metastatic melanoma. Based on this response, Iovance expects to request a pre-BLA meeting in July and to complete a BLA submission for lifileucel by August 2022. The company also announced plans to start a Phase 3 study for lifileucel in combination with Merck & Co., Inc''s (NYSE: MRK ) Keytruda for the treatment of immune checkpoint inhibitor-naïve frontline metastatic melanoma in late 2022. The stock was adding 4.11% to $17.24 in premarket trading. Kintor Announces Positive Phase 3 Results For COVID-19 Treatment Candidate Chinese biopharma Kintor Pharmaceutical Limited (OTC: KNTPF ) announced positive topline results from a Phase 3 study of proxalutamide in outpatients with mild-to-moderate COVID-19, regardless of vaccination status and risk factors.
Iovance Outlines Frontline Melanoma Strategy For Lifileucel / Pembrolizumab Combo Therapy 2022/04/06 10:18:37 Benzinga
The FDA has provided feedback regarding Iovance Biotherapeutics Inc''s (NASDAQ: IOVA ) proposed matrix of potency assays for its upcoming Biologics License Application (BLA) for lifileucel in metastatic melanoma. The company received positive feedback from the FDA on its potency assay matrix and its proprietary cell co-culture assay included in the potency assay matrix. Based on this response, Iovance expects to … Full story available on Benzinga.com
Iovance Biotherapeutics Announces Regulatory and Clinical Updates for Lifileucel in Melanoma 2022/04/05 20:05:00 Benzinga
Positive FDA Feedback on Potency Assay Matrix to Support BLA Submission Further Defines Frontline Melanoma Strategy for Lifileucel in Combination with Pembrolizumab SAN CARLOS, Calif., April 05, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA ), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that the U.S. Food and Drug Administration (FDA) has provided feedback on April 1, 2022 regarding Iovance''s proposed matrix of potency assays for its upcoming Biologics License Application (BLA) for lifileucel in metastatic melanoma. Iovance received positive feedback from the FDA on both its potency assay matrix and its proprietary cell co-culture assay included in the potency assay matrix. Based on this response, Iovance expects to request a pre-BLA meeting in July 2022 and to complete a BLA submission for lifileucel by August 2022. Frederick Vogt, Ph.D., J.D., Interim President and Chief Executive Officer of Iovance, stated, "The favorable feedback received from the FDA on our potency assays and assay matrix brings Iovance a step closer to our submission of a BLA for lifileucel in metastatic melanoma.